Maxillofacial Plastic and Reconstructive Surgery

Korean Association of Maxillofacial Plastic and Reconstructive Surgeons (대한악안면성형재건외과학회)
권호 표지

CONCOMITANT INHIBITION OF EPIDERMAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASES IN ORAL SQUAMOUS CELL CARCINOMA

구강 편평상피세포암에서 상피성장인자 수용체와 혈관내피성장인자 수용체 타이로신 활성화효소의 동시 억제

  • Park, Young-Wook (Department of Oral and Maxillofacial Surgery, College of Dentistry, Kangnung National University) ;
  • Lee, Sang-Shin (Department of Oral Pathology, College of Dentistry, Kangnung National University)
  • 박영욱 (강릉대학교 치과대학 구강악안면외과학교실) ;
  • 이상신 (강릉대학교 치과대학 구강병리학교실)
  • Published : 2006.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

Squamous cell carcinoma(SCC) of head and neck(SCCHN) is the sixth most common human malignant tumor. However, despite advances in prevention and treatment of SCC, the five-year survival rates for patients remain still low. To improve the outcome for patients with SCCHN, novel treatment strategies are needed. Overexpression of the epidermal growth factor(EGF) and activation of its receptor(EGFR) are associated with progressive growth of SCCHN. Vascular endothelial growth factor(VEGF) signaling molecules are related with neoangiogenesis and vascular metastasis of SCC. In this study, we determined the therapeutic effect of AEE788(Novartis Pharma AG, Basel, Switzerland), which is a dual inhibitor of EGFR/ErbB2 and VEGFR tyrosine kinases, on human oral SCC. At first, we screened the expression of EGFR, c-ErbB2(HER-2) and VEGFR-2 in a series of human oral SCC cell lines. And then we evaluated the effects of AEE788 on the phosphorylation of EGFR and VEGFR-2 in a oral SCC cell line expressing EGFR/HER-2 and VEGFR-2. We also evaluated the effects of AEE788 alone, or with paclitaxel(Taxol) on the oral SCC cell growth and apoptosis. As a result, all oral SCC cells expressed EGFR and VEGFR-2. Treatment of oral SCC cells with AEE788 led to dose-dependent inhibition of EGFR and VEGFR-2 phosphorylation, growth inhibition, and induction of apoptosis. Moreover, AEE788 sensitizes the cells to paclitaxel-mediated toxicity and apoptosis. These data mean EGFR and VEGFR-2 can be reliable targets for molecular therapy of oral SCC, and therefore warrant clinical use of EGFR/VEGFR inhibition in the treatment of patients with recurrent or metastatic oral SCC.

Keywords

References

  1. Parkin DM, Pisani P, Ferlay J : Global cancer statistics. CA Cancer J Clin 49 : 33, 1999 https://doi.org/10.3322/canjclin.49.1.33
  2. Goepfert H : Squamous cell carcinoma of the head and neck: past progress and future promise. CA Cancer J Clin 48 : 195, 1998 https://doi.org/10.3322/canjclin.48.4.195
  3. Salomon DS, Brandt R, Ciardiello F et al : Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 : 183, 1995 https://doi.org/10.1016/1040-8428(94)00144-I
  4. Rusch V : Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3 : 515, 1997
  5. Santini J : Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13 : 132, 1991 https://doi.org/10.1002/hed.2880130209
  6. O-charoenrat P, Phys-Evans PH, Archer DJ et al : C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol 38 : 73, 2002 https://doi.org/10.1016/S1368-8375(01)00029-X
  7. Werkmeister R, Brandt B, Joos U : Clinical relevance of erbB-1 and -2 oncogenes in oral carcinomas. Oral Oncol 36 : 100, 2000 https://doi.org/10.1016/S1368-8375(99)00069-X
  8. Rubin GJ : Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 : 824, 1998 https://doi.org/10.1093/jnci/90.11.824
  9. Magne N, Fischel JL, Dubreuil A : Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 86 : 819, 2002 https://doi.org/10.1038/sj.bjc.6600103
  10. Myers JN, Holsinger FC, Bekele BN : Targeted molecular therapy for oral cancer with epidermal growth factor receptor blockade. Arch Otolaryngol Head Neck Surg 128 : 875, 2002 https://doi.org/10.1001/archotol.128.8.875
  11. Baselga J, Rischin D, Ranson M : Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20 : 4292, 2002
  12. Cohen EE, Rosen F, Stadler WM et al : Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21 : 1980, 2003 https://doi.org/10.1200/JCO.2003.10.051
  13. Herbst RS, Shin DM : Monoclonal antibodies to target epidermal growth factor receptor-positive tumors (a new paradigm for cancer therapy). Cancer 94 : 1593, 2002 https://doi.org/10.1002/cncr.10372
  14. Baillie R : Expression of vascular endothelial growth factor in normal and tumour oral tissues assessed with different antibodies. Histochem J 33 : 287, 2001 https://doi.org/10.1023/A:1017929124317
  15. Michi Y : Human oral squamous cell carcinoma cell lines promote angiogenesis via expression of vascular endothelial growth factor and upregulation of KDR/flk-1 expression in endothelial cells. Oral Oncol 36 : 81, 2000 https://doi.org/10.1016/S1368-8375(99)00059-7
  16. Traxler P, Allegrini PR, Brandt R et al : AEE788 : A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 64 : 4931, 2004 https://doi.org/10.1158/0008-5472.CAN-03-3681
  17. Swan EA, Jasser SA, Holsinger FC et al : Acquisition of anoikis resistance is a critical step in the progression of oral tongue cancer. Oral Oncol 39 : 648, 2003 https://doi.org/10.1016/S1368-8375(03)00049-6
  18. Nicoletti I, Migliorati G, Pagliacci MC et al Z : A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139 : 271, 1991 https://doi.org/10.1016/0022-1759(91)90198-O
  19. Lynch TJ, Bell DW, Sordella R et al : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350 : 2129, 2004 https://doi.org/10.1056/NEJMoa040938
  20. Molena G, De Meijer DK, Leij LF : Tumor vasculature targeted therapies: getting the players organized. Biochem. Pharmacol 55 : 1939, 1997 https://doi.org/10.1016/S0006-2952(98)00011-2
  21. Jones AS : Neoplastic chemotherapy and head and neck cancer. J Laryngol Otol 111 : 607, 1997
  22. Well SA : EGF receptor. Int J Biochem Cell Biol 31 : 637, 1999 https://doi.org/10.1016/S1357-2725(99)00015-1
  23. Yarden Y, Sliwkowski MX : Untangling the ErbB signaling network. Nat Rev Cell Biol 2 : 127, 2001 https://doi.org/10.1038/35052073
  24. Ford AC, Grandis JR : Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 25 : 67, 2003 https://doi.org/10.1002/hed.10224
  25. Huang SM, Bock JM, Harari PM : Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 : 1935, 1999
  26. Neuchrist C, Erovic BM, Handisurya A et al : Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. The Laryngoscope 111 : 1834, 2001 https://doi.org/10.1097/00005537-200110000-00031
  27. Neuchrist C, Quint C, Pammer A et al : Vascular endothelial growth factor (VEGF) and microvessel density in squamous cell carcinomas of the larynx: an immunohistochemical study. Acta Otolaryngol 119 : 732, 1999 https://doi.org/10.1080/00016489950180711
  28. Woodburn JR : The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82 : 241, 1999 https://doi.org/10.1016/S0163-7258(98)00045-X
  29. Ciardiello F, Tortora G : A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7 : 2958, 2001
  30. Nihei Y, Suzuki M, Okano A et al : Evaluation of antivascular and antitumor effects of tubulin binding agents in solid tumor therapy. Jap J Cancer Res 90 : 1387, 1999 https://doi.org/10.1111/j.1349-7006.1999.tb00724.x
  31. Kerr DJ, Maughan T, Newlands E et al : Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma. Br J Cancer 60 : 104, 1989 https://doi.org/10.1038/bjc.1989.230
  32. Matsuno F, Haruta Y, Kondo M et al : Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new antiendoglin monoclonal antibodies. Clin Cancer Res 5 : 371, 1999
  33. Wedge SR, Ogilvie DJ, Dukes M et al : ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62 : 4645, 2002
  34. Nelson JM, Fry DW : Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J Biol Chem 276 : 14842, 2001 https://doi.org/10.1074/jbc.M008786200
  35. Pollack VA, Savage DM, Baker DA et al : Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291 : 739, 1999
  36. Williams KJ, Telfer BA, Stratford IJ et al : ZD1839 ('Iressa'), a specific oral epidermal growth factor receptortyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 86 : 1157, 2002 https://doi.org/10.1038/sj.bjc.6600182
  37. Mekhail TM, Markamn M : Paclitaxel in cancer therapy. Exper Opin Pharmacother 3 : 755, 2002 https://doi.org/10.1517/14656566.3.6.755
  38. Kawakami K, Tsukuda M, Mizuno H et al : Alteration of the Bcl-2/bax status of head and neck cancer cell lines by chemotherapeutic agents. Anticancer Res 19 : 3927, 1999